anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to 1-o-[3-aryl substituted-acrylyl]quinic acid compounds having the formula of (I), and an application thereof. The invention also relates to a preparation method of the quinic acid compounds, and intermediate compounds (II) of the quinic acid compound, i.e. 1-o-[3-aryl substituted-acrylyl]-3,4-o-isopropylidene quinic acid-1.5-lactone. The invention relates to pharmaceutical application of the quinic acid compounds, and pharmaceutical compositions containing the same. The compounds having the formula (I) and the compounds having the formula of (II), and pharmaceutical salts thereof have the effects of inhibiting hepatitis B virus DNA replication and reducing hepatitis B virus surface antigen expression. Thus, the compounds having the formula of (I) and the compounds having the formula of (II) have pharmaceutical prospect application in the preparation of a drug for preventing and treating hepatitis B virus infectious disease.
The 28-day pill pack accommodates a SUNDAY START only. Pick a time of day which will be easy to remember.

SUNDAY START: 

These instructions are for the 28-day pill pack.

  1. Take the first "active" light orange pill of the first pack on the Sunday after your period starts, even if you are still bleeding. If your period begins on Sunday, start the pack that same day. 
  2. Use another method of birth control as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms, spermicide, or the sponge are good back-up methods of birth control.
The invention belongs to the technical field of medicines, and relates to a purifying method of a uyghur traditional Chinese medicine, namely purslane seed total flavone resin. The purifying method comprises the following steps: carrying out column chromatography isolation on a purslane seed extracting solution by using a macroporous resin adsorption method, eluting, collecting eluant, concentrating, and drying so as to obtain the purified purslane seed total flavone. The purifying method of the purslane seed total flavone resin, provided by the invention, adopts dry process sample addition and is a simple, convenient and fast method. Selected macroporous resin has large adsorption capacity and high desorption rate. Alcohol is used as a solvent in the method and is low in cost and non-toxic. The purifying method is used for purifying the purslane seed extractive, so that the transfer rate of the total flavone can reach above 90%, the content of the total flavone in the purified matter can reach above 60%, and the total flavone has good repeatability; and the resin can be repeatedly used.
Study participants will be randomized to one of two parallel study arms, involving dosing of tenofovir disoproxil sodium/emtricitabine (TDF/FTC). The investigators will be recruiting and enrolling in the late 1st (preferred) and 2nd trimesters of pregnancy to capture the changes in kidney function and blood flow through the kidneys that appear to start in the late 1st trimester and are most significant in the 2nd and 3rd trimesters of pregnancy. Given the unknown time frame for the return to pre-pregnancy physiologic state and the increased risk of HIV acquisition postpartum, participants will be continued on study dose PrEP until after participants' 1-3 week postpartum visit, after which all participants will be dispensed standard dose PrEP. A 6-12 week postpartum study visit will also be performed to evaluate the timing of return to non-pregnant plasma drug levels during the postpartum period.

PK Sampling. Primary PK data will be derived from up to 7 study visits with PK sampling, including two PK visits in each trimester and postpartum. All PK visits sample blood before an observed PrEP dose. .

Safety Sampling. Maternal safety assessments will continue until 6 months postpartum. Fetal evaluation includes non-invasive limited ultrasound (US) and biophysical profiles (BPP) at study visits and 2nd and 3rd trimester interval growth US, and chart review of all before birth assessments. At birth, the investigators will obtain cord blood plasma to assess for mitochondrial function. Infant safety assessments will continue until 1 year of life. Infants will undergo swaddled Dual-energy X-ray absorptiometry (DXA) scans (without sedation) at 3-6, 24-28, and 50-54 weeks of age. The investigators will assess kidney function by blood sample at 3-6 weeks of life and repeated at 24-28 weeks.
All basic information was collected in the first trimester, and all subjects underwent OGTT (75g glucose) at 24-28 weeks of gestation. GDM will be diagnosed using the criteria of the IADPSG. At four time points during pregnancy (6-13 weeks, 24-28 weeks, 36-weeks before delivery, and 6 weeks after delivery), blood samples of 5ml were collected from each subject at each time point without increasing the number of blood samples. In the GDM group, blood samples were collected at the same time during routine visit 6 weeks after delivery. The relevant broad metabolomics and targeted vitamin profiles were also detected.
This is a Phase I, open-label trial to investigate the single-dose pharmacokinetics of telaprevir (TVR) in 12 participants with severe renal impairment (defined as creatinine clearance (CrCl) \< 30 mL/min) as compared to 12 participants with normal renal function, matched for sex, race, age (± 10 years) and BMI (± 20%). Open-label means that the study doctor and the participants know what treatment will be assigned to them. All participants will receive a single 750-mg dose of TVR. Pharmacokinetic profiles of total TVR up to 24 hours postdose will be determined. A 24 hour urine collection test will be performed to estimate the CrCl. In addition, the effect of severe renal impairment on the total and unbound plasma concentrations of the sum of TVR and VRT-127394 will be assessed. Tolerability and safety of TVR will be assessed throughout the trial period. Illnesses and side effects will be checked at every visit. Blood and urine samples will be taken at screening, on Day 1, 2 and at the 2 follow-up visits. ECG and vital signs will be taken at screening, twice on day 1, on day 2 and at the first follow-up visit. At the second follow-up visit vital signs alone will be determined. A physical examination will be done at screening, on the day before TVR intake, on day 2 and at both follow-up visits. All participants will receive a single 750-mg dose of telaprevir (TVR) given by mouth as 2 tablets of 375 mg.
The invention relates to a plaster for treating rheumatalgia and scapulohumeral periarthritis. The plaster is characterized by being mainly prepared from the following raw materials in parts by weight: 20-40 parts of radix aconite, 30-50 parts of root of common peony, 40-60 parts of radix angelicae, 30-80 parts of fructus forsythiae, 50-80 parts of honeysuckle, 30-50 parts of Bletilla striata, 30-50 parts of cinnamon, 40-80 parts of turmeric, 40-60 parts of pseudo-ginseng, 20-40 parts of Chinese honey locust, 40-80 parts of Chinese Starjasmine stems, 30-50 parts of dragon's blood, 80-100 parts of Alangium platanifolium and 70-90 parts of rhizoma smilacis glabrae. The preparation method of the plaster comprises the following steps: soaking the medicines in sesame oil for 5-7 days; decocting by moderate heat till the decoction is brown; filtering the medicines to obtain medicine oil; decocting the medicine oil by strong fire; stirring the medicine oil by a peach branch, a plum branch, a willow branch, a Chinese scholar tree branch or a mulberry branch; cooking till water drops into beads; and putting the medicine oil on oil paper to obtain the plaster. During use, the plaster is applied to the affected part and changed every 1-2 days in summer and 3-5 days in winter. Seven days are a course of treatment. After two courses of treatment, 70-90% of patients substantially regain the health. The plaster provided by the invention is simple to prepare, convenient to use, quick-acting, good in effect, capable of relieving pains and low in cost, can effectively treat arthralgia such as rheumatalgia, scapulohumeral periarthritis and osteoproliferation, and meanwhile can be used for treating traumatic injuries.
The present technology relates to a medication history information management device and a method, a registration terminal device and a method, and a program that are designed to improve convenience of use while maintaining security. When there is a request for registration of a mobile terminal device, a data center associates an individual-based terminal ID for identifying the mobile terminal device with a personal identification ID for identifying the user, and records the individual-based terminal ID. The data center also associates registration date information and organization information with the individual-based terminal ID, and records the registration date information and the organization information. For the newly registered mobile terminal device, the data center further generates registration notification information in accordance with the registration date information and the organization information, and transmits the registration notification information to a member store terminal device. The member store terminal device displays the registration notification information received from the data center. The present technology can be applied to information processing devices.
Red blood cell (RBC) transfusion is a common therapeutic approach, and almost 85 million packed red blood cells (pRBCs) are transfused annually worldwide.Transfusion efficacy largely depends on the patient's general health, but the composition of transfused pRBCs also can have an impact. pRBCs are prepared from donated whole blood and can be stored for up to 35 days.During storage, modifications of RBCs occur and affect product quality. Among other changes, these "storage lesions" induce microparticle (MP) formation. MPs are membrane particles measuring 0.1 to 1 µm produced by stimulated or apoptotic cells through modulation of membrane lipid organization and cytoskeleton reorganization. MPs can be produced from any cell type and express antigens characteristic of their original cell. Blood contains platelet-derived MPs (PMPs), which are the most frequent; RBC (erythrocyte)-derived MPs (ERMPs), representing 4% to 8% of total blood MPs; and, more rarely, MPs produced by endothelial cells and leukocyctes. In vivo, aging RBCs release ERMPs over their whole life cycle as a preventive effect of phagocytosis by macrophages. It seems that MPs quickly spread through the body, leading to a variety of biological effects by contact and interactions with many cells. MPs are well-known bioeffectors that mediate strong procoagulant potential, mainly because of phosphatidylserine and tissue factor expression. In this way, MPs are involved in coagulation disorders associated with atherothrombosis and cardiovascular diseases.Their ability to modulate inflammatory and immune responses is increasingly being studied as well as their capacity to carry and transport RNA, DNA, major histocompatibility complex molecules, and infectious agents. Moreover, depending on the type of stimulation that induces MP production, the size and biological functions of the MP can vary.
Disclosed herein is a method of promoting neuronal outgrowth in a neuron. The method comprises contacting the neuron with an effective amount of hypoxanthine, to thereby promote neuronal outgrowth of the neuron. The hypoxanthine may be contacted in the absence of xanthine oxidase and/or in the absence of exogenous nerve growth factor (NGF), and/or in the absence of exogenous D-mannose, and/or in the absence of exogenous oncomodulin, and/or in the absence of exogenous TGF-B. The neuron may be an optic nerve neuron or a retinal neuron and/or an injured neuron. Neurons may be from the central nervous system (CNS) or the peripheral nervous system (PNS). The methods are useful for treating an injured neuron, for example to an optic nerve neuron, resulting from branch and central vein/artery occlusion, trauma, edema, angle-closure glaucoma, open-angle glaucoma. Methods of treatment of various neurological injuries and diseases, as well as therapeutic compositions, are also disclosed.
Hypersensitivity pneumonitis is a syndrome that results in the excessive immune response to inhalation of various antigenic particles in the environment. Patients often experience irreversible physiological disorders and severe dyspnea in the future. Common disorders in these patients are lung function abnormalities, decreased exercise capacity, muscle weakness, oxygen diffusion limitation, impaired quality of life, physical inactivity and fatigue. The aim of this study is to evaluate the effects of pulmonary rehabilitation training on exercise capacity, dyspnea, respiratory functions, respiratory and peripheral muscle strength, inspiratory muscle endurance, physical activity level, quality of life, fatigue, dyspnea, anxiety, depression in patients with chronic fibrotic hypersensitivity pneumonitis. The study was planned as a prospective, double-blind, case-control study. At least 30 patients with hypersensitivity pneumonitis will be included in the study. The cardiopulmonary rehabilitation program will be included inspiratory muscle training, upper extremity aerobic exercise and progressive resistance training will be performed in the exercise training group during 24 sessions. Alternative upper extremity exercises combined with breathing exercises will be performed in the control group. Functional exercise capacity, respiratory functions, respiratory and peripheral muscle strength, inspiratory muscle endurance, physical activity levels, quality of life, fatigue, dyspnea, anxiety and depressions will be evaluated before and after treatment.
Hyaline cartilage fibrosis is typically considered an end-stage pathology of osteoarthritis (OA), which results in changes to the extracellular matrix. However, the mechanism behind this is largely unclear. Here, we found that the RNA helicase DDX5 was dramatically downregulated during the progression of OA. DDX5 deficiency increased fibrosis phenotype by upregulating COL1 expression and downregulating COL2 expression. In addition, loss of DDX5 aggravated cartilage degradation by inducing the production of cartilage-degrading enzymes. Chondrocyte-specific deletion of Ddx5 led to more severe cartilage lesions in the mouse OA model. Mechanistically, weakened DDX5 resulted in abundance of the Fn1-AS-WT and Plod2-AS-WT transcripts, which promoted expression of fibrosis-related genes (Col1, Acta2) and extracellular matrix degradation genes (Mmp13, Nos2 and so on), respectively. Additionally, loss of DDX5 prevented the unfolding Col2 promoter G-quadruplex, thereby reducing COL2 production. Together, our data suggest that strategies aimed at the upregulation of DDX5 hold significant potential for the treatment of cartilage fibrosis and degradation in OA.
The results of the study of genetic polymorphisms performed in renal transplant patients at our hospital demonstrated the influence of CYP3A5 \* 3 and CYP3A4 \* 22 single nucleotide polymorphism (SNPs) on exposure to Tac. From these results, the first population pharmacokinetic model was developed, which included CYP3A5 \* 3 and CYP3A4 \* 22 polymorphisms as well as hematocrit as explanatory variables of interindividual variability. Based on our population model and using the simulation tool, the percentage of patients reaching the therapeutic target based on Co values within the range of 6-10 ng / mL was determined after being dosed according to the strategy of Conventional dosage empirically according to Co achieved. The simulation of 50 Co values according to the conventional dosage allowed to determine the proportion of patients reaching the therapeutic target in each case and their confidence interval. 40% of the patients did not reach the therapeutic objective. Based on the clusters of the two polymorphisms, the percentages of patients on or below exposed varied according to whether they were slow or fast metabolizers respectively. Due to this high variability in Tac PK, the individualization of the Tac posology was calculated by calculating the initial dose according to the population model previously developed and adjusting the subsequent doses, as a function of the Tac Co through Bayesian approximations with the inclusion of genotyping and Hematocrit, can contribute greatly to achieve optimal exposure to the drug from the start of treatment in the immediate post-transplant and reduce the variability observed in the Co-achieved; This may be particularly important for patients with a slow and rapid metabolizer profile. All of this may contribute to minimizing adverse effects, ensuring greater efficacy in the target population, reducing the risk of acute rejection, and reducing associated costs.

In the present study we intend to incorporate pharmacogenomics for its application in de novo patients, which will allow us to perform a more individualized therapy for each patient based on the values of target Co and the CYP3A5 \* 3 and CYP3 A4 \* 22 polymorphisms of the patient since The initiation of immunosuppressive therapy and thus improve efficiency and decrease adverse effects.
Prolonged manned space flight exposure risks to galactic comic radiation, has led to uncertainties in a variety of health risks. Our previous work, utilizing either single ion or multiple ion radiation exposure conducted at the NSRL (NASA Space Radiation Laboratory, Brookhaven, NY) demonstrated that HZE ion components of the GCR result in persistent inflammatory signaling, increased mutations, and higher rates of cancer initiation and progression. With the development of the 33-beam galactic cosmic radiation simulations (GCRsim) at the NSRL, we can more closely test on earth the radiation environment found in space. With a previously used lung cancer susceptible mouse model (K-rasLA-1), we performed acute exposure experiments lasting 1-2 h, and chronic exposure experiments lasting 2-6 weeks with a total dose of 50 cGy and 75 cGy. We obtained histological samples from a subset of mice 100 days post-irradiation, and the remaining mice were monitored for overall survival up to 1-year post-irradiation. When we compared acute exposures (1-2 hrs.) and chronic exposure (2-6 weeks), we found a trend in the increase of lung adenocarcinoma respectively for a total dose of 50 cGy and 75 cGy. Furthermore, when we added neutron exposure to the 75 cGy of GCRsim, we saw a further increase in the incidence of adenocarcinoma. We interpret these findings to suggest that the risks of carcinogenesis are heightened with doses anticipated during a round trip to Mars, and this risk is magnified when coupled with extra neutron exposure that are expected on the Martian surface. We also observed that risks are reduced when the NASA official 33-beam GCR simulations are provided at high dose rates compared to low dose rates.
SiO2 base for dentifrice has a specific surface area of 270-500 m3/g (anhydride) determined by the BET method and 5-60 m2/g. (anhydride) determined by the CTAB method, gives an essentially amorphous X ray diffraction pattern after baking at 1100 deg.C., and has a refractive index of 1.455-1.470. In the dentifrice SiO2 base mfr., there is involved a reaction of an alkali metal silicate soln. with HCl or sulphuric acid in the presence of an electrolyte comprising (i) a SiO2 deposition step with the reaction system pH at up to 10.0: and (ii) an acidification step in which the reaction end pH is 3.5 or less and the ratio of the HCl or sulphuric acid ion addn. rate to the addn. rate in the SiO2 deposition step is at least 3:2, and which is effected within 30 minutes.
BACKGROUND: Although there have been reports of COVID-19 breakthrough infections in vaccinated individuals, the vaccines have demonstrated a high efficacy in preventing severe illness and death. Nepal has reported fewer studies of COVID-19 breakthrough infections. Hence, this study has objective to assess the prevalence, and to describe clinical characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) breakthrough infection.
METHODS: This descriptive study was conducted from January to December 2022. The study enrolled 200 individuals who had received the recommended doses of the COVID-19 vaccine and they were RT-PCR positive diagnosed with vaccine breakthrough infections after 14 days of completing the vaccination course. The patient's demographic and clinical profiles, as well as their outcomes in terms of severity, length of hospital stay, and mortality were recorded.
RESULTS: The prevalence of SARS-CoV2 infection was 6.3% (547/8682). Among fully vaccinated personnel, the prevalence of breakthrough infections was 6.2% (200/3175). This study found the Omicron variants in respondents. The mean age of the patients was 38.28 years, and 41.5% (83/200) of the breakthrough cases were healthcare workers. The mean time gap between the second dose of vaccination and a positive RT-PCR test was 354.68 days. Of the 200 breakthrough cases, 89% (178) had mild symptoms, 9% (17) had moderate symptoms requiring hospitalization, and 2% (4) were severe cases that required intensive care facility. Among the severe cases, 3 out 4 were above 60 years old. Furthermore, the patients greater than 60 years had longer hospital stays (p < 0.0001) however no deaths were recorded.
CONCLUSION: Fully vaccinated individuals can experience COVID-19 breakthrough infections and the majority of cases present with mild symptoms. Elderly patients have a higher likelihood of severe disease and longer hospital stay compared to younger patients. The results of this study emphasize the importance of vaccination in mitigating the severity of the disease.
A pill for expelling dampness and treating leucorrhea is a high-tech product which is specially used to treat gynopathy in the present invention. Prior to the invention, there are a lot of drugs for treating female's yellow leukorrhea in the market. Different from the former drugs, the product provided by the invention belongs to a pure traditional Chinese medicinal preparation and can be used to treat both symptoms and root causes. Though the former drugs have some effects of treating female's yellow leukorrhea, the effects are not obvious or ideal. The product is prepared from 12 Chinese herbal medicines of Chinese yam, Cornus officinalis, Amur Corktree Bark, bighead atractylodes rhizome, combined spicebush, fried dipsacus root, Poria cocos, Plantain seed and the like. As the product has effects of removing heat, eliminating dampness, invigorating the circulation of blood, promoting hemogenesis and haemostasis, removing stasis and expelling toxin, it can have a special effect of treating leukorrhea with yellow, white and bloody discharge.
The efficacy of Proleukin was evaluated in two hundred fifty-five patients with metastatic renal cell carcinoma (mRCC) in 7 clinical studies conducted at 21 institutions (mRCC studies). Eligible patients had an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 and normal organ function as determined by cardiac stress test, pulmonary function tests, and creatinine ≤1.5 mg/dL. Studies excluded patients with brain metastases, active infections, organ allografts, and diseases requiring steroid treatment. Not all patients in these studies received the recommended Proleukin dosing regimen.

The major efficacy outcome measure was objective response rate (ORR) determined by investigator assessment per ECOG response criteria for solid tumors (1982).

Efficacy results are summarized in Table 5.